

1 **Regulatory T cells in melanoma revisited by a computational clustering of FOXP3⁺ T cell**
2 **subpopulations¹**
3

4 Hiroko Fujii^{*}, Julie Josse[†], Miki Tanioka^{*}, Yoshiki Miyachi^{*}, François Husson[‡], and Masahiro
5 Ono^{**¶2}
6

7 ^{*} Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

8 [†] Laboratoire de mathématiques appliquées, Agrocampus Ouest, Rennes, France

9 [‡] Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, Sir Alexander Fleming
10 Building, Exhibition Road, London, SW7 2AZ, United Kingdom

11 [¶] Immunobiology, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, United Kingdom
12

13 1 This work was supported by a David Phillips Fellowship (BB/J013951/1) from the Biotechnology and
14 Biological Sciences Research Council (BBSRC), and also partly by a Long-Term Fellowship from the Human
15 Frontier Science Program.
16

17 2 Address correspondence and reprint requests to Dr. Masahiro Ono, Department of Life Sciences, Sir
18 Alexander Fleming Building, Imperial College London, Imperial College Road, London, SW7 2AZ, United
19 Kingdom. E-mail address: m.ono@imperial.ac.uk
20

21 Running title: Computational clustering of FOXP3⁺ T cell subpopulations
22

23 Abbreviations used in this paper: Treg, regulatory T cells; HDDC, high-dimensional data clustering;
24 MFI, mean fluorescence intensity; HC, healthy control.
25

1 **Abstract**

2
3 CD4⁺ T cells that express the transcription factor FOXP3 (FOXP3⁺ T cells) are commonly regarded
4 as immunosuppressive regulatory T cells (Treg). FOXP3⁺ T cells are reported to be increased in
5 tumour-bearing patients or animals, and considered to suppress anti-tumour immunity, but the
6 evidence is often contradictory. In addition, accumulating evidence indicates that FOXP3 is induced
7 by antigenic stimulation, and that some non-Treg FOXP3⁺ T cells, especially memory-phenotype
8 FOXP3^{low} cells, produce proinflammatory cytokines. Accordingly, the subclassification of FOXP3⁺ T
9 cells is fundamental for revealing the significance of FOXP3⁺ T cells in tumour immunity, but the
10 arbitrariness and complexity of manual gating have complicated the issue. Here we report a
11 computational method to automatically identify and classify FOXP3⁺ T cells into subsets using
12 clustering algorithms. By analysing flow cytometric data of melanoma patients, the proposed method
13 showed that the FOXP3⁺ subpopulation that had relatively high FOXP3, CD45RO, and CD25
14 expressions was increased in melanoma patients, whereas manual gating did not produce significant
15 results on the FOXP3⁺ subpopulations. Interestingly, the computationally-identified FOXP3⁺
16 subpopulation included not only classical FOXP3^{high} Treg but also memory-phenotype FOXP3^{low}
17 cells by manual gating. Furthermore, the proposed method successfully analysed an independent
18 dataset, showing that the same FOXP3⁺ subpopulation was increased in melanoma patients,
19 validating the method. Collectively, the proposed method successfully captured an important feature
20 of melanoma without relying on the existing criteria of FOXP3⁺ T cells, revealing a hidden
21 association between the T cell profile and melanoma, and providing new insights into FOXP3⁺ T
22 cells and Treg.

23

24

1 Introduction

2 Regulatory T cells (Treg) are defined as the immunosuppressive T cells that suppress the activities of
3 other T cells **through** undefined mechanisms, and are identified by the transcription factor FOXP3
4 (1). While Treg are reported to be increased in tumour-bearing patients or animals, and thereby
5 suppress anti-tumour immunity (2-4), the evidence is in fact mixed (5): the increase of FOXP3⁺ T
6 cells is associated with poor prognosis in hepatocellular cancer (6), whereas it is related to good
7 prognosis in colorectal cancer (7). The discrepancy may be explained by that FOXP3⁺ T cells include
8 not only regulatory but also non-regulatory T cells that produce proinflammatory cytokines (8). In
9 fact, accumulating evidence indicates that FOXP3 is not the definitive marker for the
10 immunosuppressive T cells in humans. The expression of FOXP3 can be induced in naïve T cells by
11 conventional anti-CD3 stimulation (9, 10). In addition, some FOXP3⁺ T cells, especially memory-
12 phenotype CD45RO⁺FOXP3^{low} cells, produce effector cytokines, and **are** not suppressive **by an *in***
13 ***vitro* assay**, suggesting that they are enriched with effector and activated T cells (9).

14
15 Accordingly, the subclassification of FOXP3⁺ T cells has been a major issue in human Treg **research**
16 (8, 9, 11-17). It was proposed that FOXP3⁺ T cells could be classified into three functionally
17 different subpopulations: CD45RO⁺(equivalent to CD45RA⁻) FOXP3^{high} T cells as classical Treg
18 with suppressive activity (9, 11); CD45RO⁻ (or CD45RA⁺) FOXP3^{low} naïve Treg (9, 12, 13); and
19 FOXP3^{low}CD45RO⁺ non-regulatory T cells (9, 14, 15). This classification has been used to analyse
20 FOXP3⁺ T cells in autoimmune diseases and cancers (8, 9, 16, 17). Unfortunately, however, the
21 definition of FOXP3⁺ subpopulations **varies** between studies, complicating the problem (18).
22 Meanwhile, recently Abbas *et al* proposed not to use new terms for Treg subpopulations, until a new
23 population has been extensively demonstrated to be unique, distinct from other populations and
24 stable, because it is likely to lead to more confusion and the further ‘jargonisation’ of immunology
25 (19). This opinion, however, ignores the fact that a clustering (classification) approach, whether
26 manual or automatic gating, is indispensable for summarising and analysing flow cytometric data
27 and thereby relating immunological profiles to biological response or disease status (20, 21).

28
29 Currently in experimental immunology, any cellular populations, including FOXP3⁺ T cells, are
30 almost always identified and analysed by *manual gating*, which is a process of identifying a cluster
31 of cells by manually drawing regions, or *gates*, in two-dimensional **(2D)** graphical representations of
32 the data (22-24). Obviously, manual gating is subjective and cannot fully use multidimensional flow

1 cytometry data, and therefore, the automatic gating using clustering methods has become an active
2 research area of bioinformatics **over** the past several years (23, 25). In fact, a preceding study
3 proposed a computational approach to identify a regulatory T cell population, precisely
4 CD4⁺CD25⁺DR⁺FOXP3⁺ cells (26), but it did not address the immunological significance of the
5 approach and that of the identified Treg population.

6

7 In this study, we aimed to establish a computational approach to identify and classify FOXP3⁺ T cells
8 into subpopulations, addressing the immunological and clinical significance of the method, and
9 thereby to revisit the fundamental subclassification of FOXP3⁺ T cells. In order to establish the
10 method, we used a dataset of PBMC from melanoma patients and healthy controls, which previously
11 identified that total FOXP3⁺ T cells increased in melanoma patients, and that FOXP3^{low} naïve Treg
12 and FOXP3^{low} non-regulatory T cells increased as the stage progressed (8). Furthermore, in the
13 current study, we have newly obtained a flow cytometric dataset of FOXP3⁺ T cells from melanoma
14 patients and healthy controls (designated as the second dataset), in order to address the efficiency of
15 the proposed method. Thus, we firstly show the clinical and immunological significance of a data-
16 oriented clustering approach to the subclassification of the FOXP3⁺ T cells.

17

18 **Materials and Methods**

19 *Patient samples*

20 All PBMC datasets were obtained from patients with malignant melanoma who were treated in the
21 Department of Dermatology of Kyoto University **Hospital**. The first dataset analysed 23 individuals
22 by FACS Calibur (BD Biosciences) (8). The second dataset analysed 19 individuals by LSR Fortessa
23 (BD Biosciences). The patients' characteristics in the second dataset are summarised in **Table I**. We
24 also obtained data from age- and sex-matched healthy controls (first dataset, n=28; second dataset,
25 n=15). This study was approved by the Medical Ethics Committee of Kyoto University, and
26 conducted in accordance with the principles of the Declaration of Helsinki. All participants provided
27 written informed consent.

28

29 *Flow cytometric analysis*

30 PBMC were isolated with Ficoll-Isopaque (LymphoprepTM; Axis-Shield, Oslo, Norway) gradient
31 centrifugation. All cells were freshly stained with the following monoclonal antibodies and analysed
32 promptly as previously described (9): FITC-conjugated anti-CD45RO (UCHL1; BD Biosciences);

1 PE-conjugated anti-CD25 (M-A251; BD Biosciences); PerCP-Cy5.5-conjugated anti-CD4 (SK3; BD
2 Biosciences); and biotinylated anti-FOXP3 (236A/E7; eBioscience, San Diego, CA) and
3 allophycocyanin–streptavidin (BD Biosciences). The second dataset (**Table I**) was obtained by LSR
4 Fortessa (BD Biosciences), using the following settings for voltage: FSC-A (319), SSC-A (335),
5 FL1-A (CD45RO, 582), FL2-A (CD25, 478), FL3-A (CD4, 742), and FL4-A (FOXP3, 676). FlowJo
6 (Tree Star) was used for manual gating.

7

8 *Automatic gating of FOXP3⁺ T cell subpopulations*

9 For data preprocessing, boundary values were removed (i.e. 1000 \geq or $<$ 100 [FSC], 1000 \geq
10 [SSC], \geq 4 or $<$ 0.3 [fluorescence channels, logged] in the case of analogue data; 800 \geq or $<$ 100
11 [FSC], 1000 \geq [SSC], and \geq 3.5 or $<$ 0.1 [fluorescence channels, logged] in the case of digital
12 data), as they were considered meaningless events representing cellular debris or large non-
13 lymphocytes, or noise (27). Subsequently, all fluorescence data were log-transformed, and each
14 variable was normalised by the standardised scaling. In the established classification method (*the*
15 *HKK clustering*), FOXP3⁺ T cell subpopulations were identified by the following three steps: [1]
16 CD4⁺ T cells were clustered by a high-dimensional data clustering function, *hddc*, of a CRAN
17 package, *HDclassif* (28) using FSC, SSC, and CD4 ($k = 3$). [2] FOXP3⁺ T cells were clustered by a
18 k-means clustering of FOXP3 values using *kmeans* of a CRAN package, *Stats* (29), and the cluster
19 containing the centroid with the highest FOXP3 value was designated as FOXP3⁺ T cells. The
20 number of clusters ($k = 3$) was determined by examining the barplot of the loss-variability (30), and
21 also, taking into account the identification of the FOXP3⁺ cluster that has higher FOXP3 values than
22 the FOXP3-negative cloud. [3] Finally, FOXP3⁺ T cell subpopulations were identified by a k-means
23 clustering, using CD45RO, CD25, and FOXP3 with $k = 3$, and subsequently assigned to the *Effector-*
24 *Treg-like*, *Naïve-Treg-like*, and *Non-Treg-like* clusters as follows: [1] compute the centroid of each
25 cluster and designate the cluster containing the centroid with the highest value for FOXP3 as
26 *effector-Treg-like*, [2] among the two other clusters, the one with the smallest value for CD45RO as
27 *naïve-Treg-like*, and the last one as *non-Treg-like*. All computational analyses were done using a
28 laptop with an Intel Core i5-3360 M CPU - 2.80 GHz or a Mac desktop with 3.5 GHz Intel Core i5,
29 OS10.10.4.

30

31 *Statistical analysis*

1 A Mann-Whitney-Wilcoxon test was used for analysing two groups, testing the null hypothesis that
2 the two statuses (i.e. HC or melanoma) have equal medians. A Kruskal-Wallis test, a non-parametric
3 alternative to ANOVA, was used for analysing more than two groups, testing the null hypothesis that
4 the medians are equal across the groups (HC and disease stages), followed by pairwise comparisons
5 using a Mann-Whitney-Wilcoxon test. P-values were adjusted by a Bonferroni procedure for
6 multiple comparisons in all the analyses.

7

8 **Results**

9 **1. Manual gating approach to FOXP3⁺ T subpopulations**

10 This section shows how the standard approach, *manual gating*, identified and classified FOXP3⁺ T
11 cells into three subsets: CD45RO⁺FOXP3^{high} effector (memory) Treg (“*effector-Treg population*”
12 hereafter), CD45RO⁻FOXP3^{low} naïve Treg (“*naïve-Treg population*”), and CD45RO⁺FOXP3^{low} non-
13 regulatory T cells (“*non-Treg population*”) (8, 9) (**Fig. 1a**). These subpopulations were identified in a
14 sequential manner using the following four gates: [1] the lymphocyte gate using Forward Scatter
15 (FSC), and Side Scatter (SSC, **Fig. 1b**); [2] the CD4⁺ gate using CD4 and SSC (**Fig. 1c**); and [3] the
16 FOXP3⁺ gate using FOXP3 and CD45RO to visually identify a “groove” of the FOXP3 distribution
17 (**Fig. 1d**); [4] the FOXP3/CD45RO gate to identify the FOXP3⁺ T cell subpopulations (**Fig. 1e**). The
18 level of FOXP3 by which FOXP3^{high} and FOXP3^{low} cells were separated was determined so that
19 CD45RO⁻FOXP3^{high} cells were < 0.2% of CD4⁺ lymphocytes using healthy controls (**Fig. 1e**).

20

21 **2. Data-oriented clustering (automatic gating) of FOXP3⁺ T cell subpopulations**

22 We aimed to establish an automated clustering method for identifying FOXP3⁺ T cells and
23 classifying them into three subpopulations, and thereby to revisit the immunological significance of
24 the FOXP3⁺ T cell classification. Importantly, there is no major controversy regarding the
25 identification of the total FOXP3⁺ CD4⁺ T cells, while there are multiple ways to classify FOXP3⁺ T
26 cells, which we aimed to address in this study. Thus, we used the following approach to identify the
27 FOXP3⁺ T cell subpopulations: [1] to identify FOXP3⁺CD4⁺ T cells, and [2] to classify
28 FOXP3⁺CD4⁺ T cells into three subpopulations without using the manual gating strategy. We used
29 the flow cytometric dataset in our previous report, which was obtained by a FACS Calibur (8) (“*the*
30 *first dataset*”), in order to establish a clustering method.

31

32 *Automatic gating of FOXP3⁺ CD4⁺ T cells*

1 The aim of this step is to efficiently and robustly identify FOXP3⁺ CD4⁺ T cells as described above.
2 CD4⁺ cells are distinct from CD4⁻ cells in the space of FSC, SSC, and CD4 (Fig. 1b, 1c), while the
3 distribution of FOXP3 expression is continuous in CD4⁺ T cells (Fig. 1d). In fact, a preliminary
4 analysis showed that CD4⁺ T cells were efficiently identified using a model of high-dimensional data
5 clustering (HDDC, (28)), but not by a common clustering method, k-means. HDDC is based on
6 Gaussian mixtures with restricted covariance matrices (28), and can efficiently identify elliptic
7 populations such as CD4⁺ T cells in the space of FSC, SSC, and CD4. On the other hand, FOXP3⁺
8 cells are not as discrete as CD4⁺ T cells, and it was not obvious what method was suitable.

9

10 Thus, we compared different combinations of the clustering methods using a resampling approach,
11 addressing the sensitivity and the accuracy of the methods. Here we compared the following
12 methods: [1] *HK clustering*: CD4⁺ T cell selection by HDDC, followed by FOXP3⁺ T cell selection
13 by k-means; [2] *HH clustering*: CD4⁺ T cell selection by HDDC, followed by FOXP3⁺ T cell
14 selection by HDDC; and [3] *one-step H clustering*: FOXP3⁺CD4⁺ T cell selection by one-step
15 HDDC. Using several random number seeds, the HK clustering showed the highest sensitivities and
16 accuracies across different cell numbers comparing to the other methods (**Fig. 2a-2g**).

17

18 *Automatic classification of the three FOXP3⁺ T cell subpopulations*

19 Next, we aimed to establish a method that subclassifies the FOXP3⁺CD4⁺ T cells into three
20 subpopulations without relying on the manual gating criteria, and thereby to readdress the
21 significance of FOXP3⁺CD4⁺ T cell subpopulations. We compared k-means and HDDC ($k = 3$;
22 designated as *HKK and HKH clustering methods*, respectively) by a resampling approach, in order to
23 identify a method that consistently assigns similar cells to each cluster, using CD45RO, CD25, and
24 FOXP3. The resampling experiment showed that the HKK clustering had smaller variations in both
25 the percentage and the mean fluorescence intensities (MFI) of CD45RO, CD25, and FOXP3 of each
26 subpopulation, than the HKH clustering (**Fig. 3a-3d**). Thus, the HKK clustering has been chosen as
27 the method for identifying and classifying the FOXP3⁺ T cell subpopulations.

28

29 The three clusters identified by the HKK clustering were partially overlapped with the three
30 subpopulations identified by manual gating. In order to make the clusters and the subpopulations
31 comparable, the cluster with the highest FOXP3 expressions was designated as *effector-Treg-like*,
32 and those with low and high CD45RO expressions were designated as *naïve-Treg-like* and *non-Treg-*

1 *like* clusters, respectively (**Fig. 3e-3f**). Obviously, the effector-Treg-like cluster contained not only
2 the cells that were identified as effector-Treg but also some of the FOXP3^{low} cells that were
3 identified as non-Treg by manual gating (**Fig. 3e-3f**). The HKK clustering was not computationally
4 expensive: it took 45 seconds per patient on average to perform all the 3 clustering steps using a
5 conventional laptop.

6
7 *Statistical comparisons of FOXP3⁺ T cell subpopulations between manual and automatic gating*

8 We compared the subpopulations that were identified by the HKK clustering with those by the
9 manual gating, in order to understand the similarities and dissimilarities of the two approaches.
10 Obviously, the HKK clustering included more cells in the effector-Treg-like cluster than manual
11 gating, while the latter included more in the non-Treg-like cluster (**Fig. 4a-4d**). The effector-Treg-
12 like and the non-Treg-like clusters showed relatively low correlations with their corresponding
13 manually-gated populations ($r = 0.6236$ and 0.7782 , respectively) (**Fig. 4e, 4f**). On the other hand,
14 the naïve-Treg-like cluster and all FOXP3⁺ T cells had high correlations with their corresponding
15 manually-gated populations ($r = 0.9168$ and 0.8947 , respectively, **Fig. 4g, 4h**). All results were
16 statistically significant ($p < 0.0001$).

17
18 Next, the HKK clustering and the manual gating approaches were compared for association with
19 melanoma. As we previously reported, the manually-gated three subpopulations, effector-Treg,
20 naïve-Treg, and non-Treg, showed a significant difference between HC and melanoma patients ($p <$
21 0.05) (8). However, assuming that the three subpopulations might be related to each other, when p -
22 values were adjusted for multiple comparisons using a Bonferroni method, all the adjusted p -values
23 exceeded 0.05 , and thus, the manually-identified subpopulations did not show significant difference
24 using the conservative approach. On the other hand, among the automatically-identified clusters, the
25 effector-Treg-like cluster was significantly increased in melanoma patients comparing to controls
26 (adjusted p -value = 0.027 , **Fig. 5**). This result suggested that the effector-Treg-like cluster by the
27 HKK clustering more efficiently captured the characteristics of melanoma patients.

28
29 *Application of automatic gating to an independent dataset*

30 Lastly, we attempted to apply the established method to an independent dataset. We have generated a
31 new dataset using a different flow cytometer, LSR Fortessa, analysing 12 healthy controls and 19
32 melanoma patients (“*the second dataset*”, **Table I**). When p -values were adjusted for the multiple

1 comparisons of the three clusters, the effector-Treg-like cluster only showed a significant increase in
2 melanoma patients comparing to HC by a Mann-Whitney-Wilcoxon test (adjusted p-value = 0.0015,
3 **Fig. 6**), confirming the results of the first dataset. Furthermore, a Kruskal-Wallis test showed that the
4 effector-Treg-like cluster only was significantly different across HC and three disease stages
5 (adjusted p-value = 0.0014, **Fig. 6a**). Pairwise comparisons of the 4 different statuses using a Mann-
6 Whitney-Wilcoxon test showed that the effector-Treg-like cluster was significantly increased in stage
7 III and stage IV comparing to HC (adjusted p-values = 0.0127 and 0.0325, respectively; **Fig. 6b**).
8

8

9 **Discussion**

10 This study has proposed to use a clustering approach to reveal the immunological profiles of
11 FOXP3⁺ T cells without invoking the concept of the immunosuppressive phenotype of FOXP3⁺ T
12 cells (19), and thereby to correlate them with disease phenotype or biological response. The current
13 dogma of Treg (i.e. *the lineage perspective*(31)) considers that a Treg population can be defined only
14 when it has been shown to be unique and distinct from other T cells and stable as a lineage (19). To
15 be compatible with the lineage perspective, the threshold level of FOXP3 for defining the effector-
16 Treg subpopulation by manual gating has been determined based on the result of a suppressive assay
17 (9), the gold standard for assessing the immunosuppressive function of Treg (32, 33). **Alarmingly**,
18 however, recent studies indicate that the “suppressive activity” by the assay is mostly explained by
19 the absorption of IL-2 in the culture by CD25 (IL-2 receptor α chain) on the surface of anergic Treg
20 (34, 35). Since FOXP3 has positive correlations with CD25 and anergy (36), it is not surprising that
21 FOXP3^{high}CD45RO⁺CD25^{high} T cells (i.e. effector-Treg by manual gating) show a high suppressive
22 activity in the *in vitro* assay.
23

23

24 The proposed method revealed that the effector-Treg-like cluster only was significantly increased in
25 melanoma patients in both of the datasets, suggesting that this cluster captured an important
26 immunological feature. These results encourage the computational clustering approach to reveal the
27 immunological features of T cells in tumour-bearing patients. On the other hand, the computationally
28 identified effector-Treg-like cluster included some memory-phenotype CD45RO⁺FOXP3^{low} non-Treg
29 cells by manual gating (Fig. 3e, 3f, 4a-4d) (8, 9). While the result is difficult to be interpreted by the
30 lineage perspective, our recently proposed model of Treg and FOXP3, *feedback control perspective*
31 (31), may be useful for reconciling the results in this study with findings on Treg in the literature.
32 Under this new perspective, the increase of the effector-Treg-like cluster in melanoma patients is

1 interpreted that FOXP3 was more frequently induced in tumour-bearing patients as a consequence of
2 antigen recognition and a negative feedback mechanism of T cell activation, which also explains the
3 memory phenotype of the effector-Treg-like cluster. Interestingly, the second dataset analysis showed
4 that the effector-Treg-like cluster was increased in higher stages of melanoma (stage III and IV, Fig.
5 6), which is interpreted by the new model that reactive FOXP3⁺ cells accumulated in the immune
6 system **as a result of** prolonged chronic stimulation by cancer cells. Although the present study is not
7 conclusive as to which perspective should be used, certainly the new perspective allows a more
8 flexible interpretation of clinical and experimental data, because it does not assume stable and
9 distinct lineages but **is more concerned with** the dynamics at the cellular and molecular levels. In
10 fact, a recent study demonstrated an extensive TCR overlap between FOXP3⁺ cells and
11 CD25⁺FOXP3⁻ cells at the site of inflammation (37), further confirming that T cells may dynamically
12 change the expression of FOXP3, especially in disease conditions. Importantly, this view leads to a
13 question whether the negative feedback mechanism is stronger than the positive feedback mechanism
14 in melanoma patients, encouraging further investigations on the latter in future studies.

15

16 The proposed clustering method provided reproducible results between two independent datasets.
17 Note that the first dataset is in FCS2.0 format, obtained by an analogue system, FACS Calibur, while
18 the second dataset is in FCS3.0 format, and was obtained by a digital acquisition system, LSR
19 Fortessa (38). While data normalisation method for such different datasets is yet to be established
20 and is a big issue in flow cytometric data analysis (39), the present study encourages **the use of** the
21 proposed method or similar clustering methods **for the analysis of** complex flow cytometric data. In
22 our analysis, CD4⁺ T cell selection was almost identical between the manual and the automatic
23 approaches (Fig. 2a). While the manual gating commonly creates a lymphocyte gate using FSC and
24 SSC, and subsequently identifies CD4⁺ T cells (Fig. 1), our investigation showed that it was more
25 efficient to identify CD4⁺ T cells by a one-step HDDC clustering approach using all FSC, SSC and
26 CD4. This indicates that CD4⁺ T cells are the most distinct when all the three dimensions are used. In
27 fact, it is a common practice in manual gating to use either FSC or SSC to create a CD4-gate (e.g.
28 Fig. 1c). This result confirms that flow cytometric data analysis in a higher dimensional space
29 enables more efficient analysis (23, 25), which is widely accepted but yet-to-be further demonstrated
30 by addressing real immunological problems. On the other hand, there is a small discordance in
31 FOXP3⁺ T cells by the manual gating and by the automatic clustering (Fig. 2b, left panel), although
32 the overall correlation was high ($r = 0.8947$, Fig. 4h). This small discordance may be related to either

1 or both of the inherent arbitrariness of the manual gating approach to the FOXP3⁺ selection and the
2 variations by k-means. Since FOXP3 is measured by intranuclear staining and therefore its
3 autofluorescence background is high (Fig 1, (9, 40)), it is experimentally difficult to precisely
4 determine the boundary between the negative cloud and positive cells without using FOXP3-
5 deficient T cells from mutant humans (41), which are practically difficult to be obtained in most
6 laboratories. In addition, even using such negative controls, it is not obvious where to set the
7 boundary. This is why the manual gating approach visually identifies a ‘groove’ between the negative
8 cloud and positive cells and sets it as a boundary for FOXP3⁺ cells (Fig. 1d). On the other hand, k-
9 means is a method to determine clusters by minimising the within-cluster sum of squares (42), and
10 thus can be affected by the distribution of cells and also by outliers, which can introduce variations.
11 The small discordance of the boundary for FOXP3⁺ cells may have contributed to those of the non-
12 Treg-like and naïve-Treg-like clusters as well, as both clusters faced the boundary of FOXP3 positive
13 and negative cells, while it presumably did not directly affect the effector-Treg-like cluster (Fig. 3e).
14 However, considering that the proposed automatic gating only identified a significant increase of the
15 FOXP3⁺ T cell subpopulation in melanoma patients, and that the manual gating did not produce any
16 significant results on the analysed subpopulations including non-Treg and naïve-Treg, the
17 immunological feature of melanoma patients most probably is in the cells with higher FOXP3
18 expressions, and the discordance in the FOXP3 boundary is probably not important in the setting.
19 Yet, it is hoped that future studies will develop data analytic and modelling methods to better deal
20 with the problem of where to set the boundary between negative and positive cells in continuous
21 distributions.

22

23 **Disclosures**

24 The authors have no financial conflicts of interest.

25

26 **Acknowledgements**

27 We thank Ms A. Bradley for proofreading the manuscript.

28

29 **Reference**

- 30 1. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune
31 tolerance. *Cell* 133: 775-787.
- 32 2. Gallimore, A., and A. Godkin. 2008. Regulatory T cells and tumour immunity - observations
33 in mice and men. *Immunology* 123: 157-163.

- 1 3. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol* 6:
2 295-307.
- 3 4. Motz, G. T., and G. Coukos. 2013. Deciphering and reversing tumor immune suppression.
4 *Immunity* 39: 61-73.
- 5 5. deLeeuw, R. J., S. E. Kost, J. A. Kakal, and B. H. Nelson. 2012. The prognostic value of
6 FoxP3⁺ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. *Clinical*
7 *cancer research : an official journal of the American Association for Cancer Research* 18:
8 3022-3029.
- 9 6. Wang, F., X. Jing, G. Li, T. Wang, B. Yang, Z. Zhu, Y. Gao, Q. Zhang, Y. Yang, Y. Wang, P.
10 Wang, and Z. Du. 2012. Foxp3⁺ regulatory T cells are associated with the natural history of
11 chronic hepatitis B and poor prognosis of hepatocellular carcinoma. *Liver Int* 32: 644-655.
- 12 7. Salama, P., M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta.
13 2009. Tumor-infiltrating FOXP3⁺ T regulatory cells show strong prognostic significance in
14 colorectal cancer. *Journal of clinical oncology : official journal of the American Society of*
15 *Clinical Oncology* 27: 186-192.
- 16 8. Fujii, H., A. Arakawa, A. Kitoh, M. Miyara, M. Kato, S. Kore-eda, S. Sakaguchi, Y. Miyachi,
17 M. Tanioka, and M. Ono. 2011. Perturbations of both nonregulatory and regulatory FOXP3⁺
18 T cells in patients with malignant melanoma. *Br J Dermatol* 164: 1052-1060.
- 19 9. Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T.
20 Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z. Amoura,
21 G. Gorochov, and S. Sakaguchi. 2009. Functional delineation and differentiation dynamics of
22 human CD4⁺ T cells expressing the FoxP3 transcription factor. *Immunity* 30: 899-911.
- 23 10. Buckner, J. H., and S. F. Ziegler. 2008. Functional analysis of FOXP3. *Ann N Y Acad Sci*
24 1143: 151-169.
- 25 11. Vukmanovic-Stejić, M., Y. Zhang, J. E. Cook, J. M. Fletcher, A. McQuaid, J. E. Masters, M.
26 H. Rustin, L. S. Taams, P. C. Beverley, D. C. Macallan, and A. N. Akbar. 2006. Human CD4⁺
27 CD25^{hi} Foxp3⁺ regulatory T cells are derived by rapid turnover of memory populations in
28 vivo. *J Clin Invest* 116: 2423-2433.
- 29 12. Seddiki, N., B. Santner-Nanan, J. Martinson, J. Zaunders, S. Sasson, A. Landay, M. Solomon,
30 W. Selby, S. I. Alexander, R. Nanan, A. Kelleher, and B. Fazekas de St Groth. 2006.
31 Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory
32 and activated T cells. *J Exp Med* 203: 1693-1700.
- 33 13. Valmori, D., A. Merlo, N. E. Souleimanian, C. S. Hesdorffer, and M. Ayyoub. 2005. A
34 peripheral circulating compartment of natural naïve CD4 Tregs. *J Clin Invest* 115: 1953-
35 1962.
- 36 14. Hall, B. M., N. D. Verma, G. T. Tran, and S. J. Hodgkinson. 2011. Distinct regulatory CD4⁺T
37 cell subsets; differences between naïve and antigen specific T regulatory cells. *Curr Opin*
38 *Immunol* 23: 641-647.
- 39 15. Feuerer, M., J. A. Hill, D. Mathis, and C. Benoist. 2009. Foxp3⁺ regulatory T cells:
40 differentiation, specification, subphenotypes. *Nat Immunol* 10: 689-695.
- 41 16. Matsuki, F., J. Saegusa, K. Nishimura, Y. Miura, M. Kurosaka, S. Kumagai, and A.
42 Morinobu. 2014. CD45RA⁺Foxp3^{low} non-regulatory T cells in the CCR7⁺CD45RA⁻
43 CD27⁺CD28⁺ effector memory subset are increased in synovial fluid from patients with
44 rheumatoid arthritis. *Cell Immunol* 290: 96-101.
- 45 17. Marwaha, A. K., S. Q. Crome, C. Panagiotopoulos, K. B. Berg, H. Qin, Q. Ouyang, L. Xu, J.
46 J. Priatel, M. K. Levings, and R. Tan. 2010. Cutting edge: Increased IL-17-secreting T cells in
47 children with new-onset type 1 diabetes. *J Immunol* 185: 3814-3818.

- 1 18. Jacobs, J. F., S. Nierkens, C. G. Figdor, I. J. de Vries, and G. J. Adema. 2012. Regulatory T
2 cells in melanoma: the final hurdle towards effective immunotherapy? *Lancet Oncol* 13: e32-
3 42.
- 4 19. Abbas, A. K., C. Benoist, J. A. Bluestone, D. J. Campbell, S. Ghosh, S. Hori, S. Jiang, V. K.
5 Kuchroo, D. Mathis, M. G. Roncarolo, A. Rudensky, S. Sakaguchi, E. M. Shevach, D. A.
6 Vignali, and S. F. Ziegler. 2013. Regulatory T cells: recommendations to simplify the
7 nomenclature. *Nat Immunol* 14: 307-308.
- 8 20. Maecker, H. T., J. P. McCoy, and R. Nussenblatt. 2012. Standardizing immunophenotyping
9 for the Human Immunology Project. *Nat Rev Immunol* 12: 191-200.
- 10 21. Rossin, E., T. I. Lin, H. J. Ho, S. J. Mentzer, and S. Pyne. 2011. A framework for analytical
11 characterization of monoclonal antibodies based on reactivity profiles in different tissues.
12 *Bioinformatics* 27: 2746-2753.
- 13 22. Mosmann, T. R., I. Naim, J. Rebhahn, S. Datta, J. S. Cavanaugh, J. M. Weaver, and G.
14 Sharma. 2014. SWIFT-scalable clustering for automated identification of rare cell
15 populations in large, high-dimensional flow cytometry datasets, part 2: biological evaluation.
16 *Cytometry A* 85: 422-433.
- 17 23. Ge, Y., and S. C. Sealfon. 2012. flowPeaks: a fast unsupervised clustering for flow cytometry
18 data via K-means and density peak finding. *Bioinformatics* 28: 2052-2058.
- 19 24. Maecker, H. T., A. Rinfret, P. D'Souza, J. Darden, E. Roig, C. Landry, P. Hayes, J. Birungi, O.
20 Anzala, M. Garcia, A. Harari, I. Frank, R. Baydo, M. Baker, J. Holbrook, J. Ottinger, L.
21 Lamoreaux, C. L. Epling, E. Sinclair, M. A. Suni, K. Punt, S. Calarota, S. El-Bahi, G. Alter,
22 H. Maila, E. Kuta, J. Cox, C. Gray, M. Altfeld, N. Nougarede, J. Boyer, L. Tussey, T. Tobery,
23 B. Brecht, M. Roederer, R. Koup, V. C. Maino, K. Weinhold, G. Pantaleo, J. Gilmour, H.
24 Horton, and R. P. Sekaly. 2005. Standardization of cytokine flow cytometry assays. *BMC*
25 *Immunol* 6: 13.
- 26 25. Cron, A., C. Gouttefangeas, J. Frelinger, L. Lin, S. K. Singh, C. M. Britten, M. J. Welters, S.
27 H. van der Burg, M. West, and C. Chan. 2013. Hierarchical modeling for rare event detection
28 and cell subset alignment across flow cytometry samples. *PLoS Comput Biol* 9: e1003130.
- 29 26. Pyne, S., X. Hu, K. Wang, E. Rossin, T. I. Lin, L. M. Maier, C. Baecher-Allan, G. J.
30 McLachlan, P. Tamayo, D. A. Hafler, P. L. De Jager, and J. P. Mesirov. 2009. Automated
31 high-dimensional flow cytometric data analysis. *Proc Natl Acad Sci U S A* 106: 8519-8524.
- 32 27. Donnenberg, D., and V. Donnenberg 2008. Understanding Clinical Flow Cytometry. In
33 *Handbook of Human Immunology*. M. O'Gorman, and A. Donnenberg, eds. CRC Press.
- 34 28. Bergé, L., C. Bouveyron, and S. Girard. 2012. HDclassif: An R Package for Model-Based
35 Clustering and Discriminant Analysis of High-Dimensional Data. *Journal of Statistical*
36 *Software* 46: 1-29.
- 37 29. R Core Team. 2015. R: A language and environment for statistical computing. R Foundation
38 for Statistical Computing. Vienna, Austria. <http://www.R-project.org/>
- 39 30. Husson, F., S. Le, and J. Pages. 2011. Clustering. In *Explanatory Multivariate Analysis by*
40 *Example Using R*. CRC Press. 169-204.
- 41 31. Ono, M., and R. J. Tanaka. 2015. Controversies concerning thymus-derived regulatory T
42 cells: fundamental issues and a new perspective. *Immunol Cell Biol*.
- 43 32. Shevach, E. M. 2000. Regulatory T cells in autoimmunity. *Annu Rev Immunol* 18: 423-449.
- 44 33. Sakaguchi, S. 2004. Naturally arising CD4⁺ regulatory T cells for immunologic self-tolerance
45 and negative control of immune responses. *Annu Rev Immunol* 22: 531-562.
- 46 34. Busse, D., M. de la Rosa, K. Hobiger, K. Thurley, M. Flossdorf, A. Scheffold, and T. Hofer.
47 2010. Competing feedback loops shape IL-2 signaling between helper and regulatory T
48 lymphocytes in cellular microenvironments. *Proc Natl Acad Sci U S A* 107: 3058-3063.

- 1 35. Smith, K. A., and Z. Popmihajlov. 2008. The quantal theory of immunity and the interleukin-
2 2-dependent negative feedback regulation of the immune response. *Immunol Rev* 224: 124-
3 140.
- 4 36. Ziegler, S. F. 2006. FOXP3: of mice and men. *Annu Rev Immunol* 24: 209-226.
- 5 37. Bending, D., E. Giannakopoulou, H. Lom, and L. R. Wedderburn. 2015. Synovial Regulatory
6 T Cells Occupy a Discrete TCR Niche in Human Arthritis and Require Local Signals to
7 Stabilize FOXP3 Protein Expression. *J Immunol*.
- 8 38. Seamer, L. C., C. B. Bagwell, L. Barden, D. Redelman, G. C. Salzman, J. C. Wood, and R. F.
9 Murphy. 1997. Proposed new data file standard for flow cytometry, version FCS 3.0.
10 *Cytometry* 28: 118-122.
- 11 39. Le Meur, N. 2013. Computational methods for evaluation of cell-based data assessment--
12 Bioconductor. *Current opinion in biotechnology* 24: 105-111.
- 13 40. Ono, M., J. Shimizu, Y. Miyachi, and S. Sakaguchi. 2006. Control of autoimmune
14 myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-
15 related protein(high), Foxp3-expressing CD25⁺ and CD25⁻ regulatory T cells. *J Immunol* 176:
16 4748-4756.
- 17 41. McMurchy, A. N., J. Gillies, M. C. Gizzi, M. Riba, J. M. Garcia-Manteiga, D. Cittaro, D.
18 Lazarevic, S. Di Nunzio, I. S. Piras, A. Bulfone, M. G. Roncarolo, E. Stupka, R. Bacchetta,
19 and M. K. Levings. 2013. A novel function for FOXP3 in humans: intrinsic regulation of
20 conventional T cells. *Blood* 121: 1265-1275.
- 21 42. Aghaeepour, N., R. Nikolic, H. H. Hoos, and R. R. Brinkman. 2011. Rapid cell population
22 identification in flow cytometry data. *Cytometry Part A* 79A: 6-13.
- 23
24

1 **Figure Legends**

2 **Fig. 1. Manual gating approach to classify the FOXP3⁺ T cell subpopulations.**

3 The manual gating approach to identify and classify FOXP3⁺ T cell subpopulations is depicted. (a)
4 Representative flow cytometric data showing the three subsets of FOXP3⁺ T cells in PBMC:
5 CD45RO⁺FOXP3^{high} effector Treg; CD45RO⁻FOXP3^{low} naïve Treg; and CD45RO⁺FOXP3^{low} non-
6 regulatory T cells (non-Treg). These subpopulations are classified in a sequential manner using the
7 following three gates: (b) the lymphocyte gate on the window displaying FSC and SSC; (c) the CD4⁺
8 gate using CD4 and SSC; (d) the FOXP3⁺ gate using FOXP3 and CD45RO; and (e) the FOXP3⁺ T
9 cell subpopulation gate using FOXP3 and CD45RO. The level of FOXP3^{high} and FOXP3^{low} cells was
10 determined so that CD45RO⁻FOXP3^{high} cells were < 0.2% of CD4⁺ T cells.

11

12 **Fig. 2. Automatic gating of FOXP3⁺CD4⁺ T cells.**

13 Three clustering methods were compared for identifying FOXP3⁺CD4⁺ T cells: (1) CD4⁺ T cell
14 selection by High-Dimensional Data Clustering (HDDC), followed by FOXP3⁺ T cell selection by k-
15 means (“HK clustering”); CD4⁺ T cell selection by HDDC, followed by FOXP3⁺ T cell selection by
16 HDDC (“HH clustering”); and (3) FOXP3⁺CD4⁺ T cell selection by one step-HDDC (“one-step H
17 clustering”). Various random number seeds were used to resample events from a flow cytometric
18 data, and resampling was repeated 100 times for each random number seed, in order to address the
19 robustness and the efficiency of the three clustering methods. Sensitivities and accuracies were
20 calculated by assuming that the manual gating provides a gold standard. (a - c) Sensitivities and
21 accuracies of HK and HH: (a) Sensitivities and accuracies for identifying CD4⁺ T cells by HDDC
22 (shared by HK and HH). (b - c) Sensitivities and accuracies of (b) k-means and (c) HDDC for
23 identifying FOXP3⁺ T cells from the identified CD4⁺ T cell cluster (HK and HH, respectively). (d)
24 Sensitivities and accuracies of HDDC for identifying FOXP3⁺ T cells from all cells (one-step H). (e -
25 g) Representative plots of automatically gated FOXP3⁺CD4⁺ T cells by the HK clustering method for
26 (e, f) CD4⁺ T cells and (g) FOXP3⁺ T cells. The clustered cells are shown by black dots.

27

28 **Fig. 3. Automatic clustering of FOXP3⁺ CD4⁺ T cell subpopulations.**

29 K-means and HDDC were used for classifying the computationally clustered FOXP3⁺ T cells into
30 three subpopulations, and compared **them** for stability using a resampling approach, which was
31 repeated 100 times. (a - d) Boxplots showing (a) the percentages and the mean fluorescence
32 intensities (MFI) of (b) CD45RO, (c) CD25, or (d) FOXP3 of each FOXP3⁺ T cell subcluster in
33 CD4⁺ T cells by either k-means or HDDC in the 100 resampled samples (i.e. HKK or HKH,

1 respectively). (e - f) Representative plots of FOXP3⁺ T cell subpopulations (e) by the HKK clustering
2 (automatic) and (f) by manual gating.

3

4 **Fig. 4. Comparison of the FOXP3⁺ T cell clusters/populations identified by the automatic and**
5 **manual gating approaches.**

6 (a-d) The automatic (the HKK clustering) and manual gating approaches were compared by
7 Spaghetti plots of the percentage of the cells that were classified as (a) effector-Treg(-like), (b) non-
8 Treg(-like) and (c) naïve-Treg(-like), and (d) all FOXP3⁺ T cells, in all samples including healthy
9 controls and melanoma patients. (e-h) Scatter plots showing the percentages of each FOXP3⁺ T cell
10 cluster/population by automatic (the HKK clustering) and manual gating: (e) effector-Treg(-like), (f)
11 non-Treg(-like) and (g) naïve-Treg(-like), and (h) all FOXP3⁺ T cells. Closed and open circles
12 represent melanoma and healthy control samples, respectively. All percentages are in CD4⁺ T cells.
13 Pearson's correlation coefficient (*r*) was calculated using all the samples for each cluster.

14

15 **Fig. 5. Effector-Treg-like cluster in HC and melanoma patients by the automatic HKK**
16 **clustering or manual gating.**

17 (a) Boxplot showing %(*effector-Treg-like*)/CD4 of HC and melanoma patients by the automatic
18 HKK clustering. * Adjusted *p* < 0.05. (b) Boxplot showing %(*effector-Treg*)/CD4 of HC and
19 melanoma patients by manual gating.

20

21 **Fig. 6. Application of the automatic gating approach to an independent dataset.**

22 The established automatic gating method, the HKK clustering, was applied to an independent dataset
23 (the second dataset, see **Table I**). (a) Boxplots showing %(*effector-Treg-like*)/CD4 in healthy control
24 (HC) and melanoma patients (***) adjusted *p* = 0.0015). (b) Boxplots showing %(*effector-Treg-*
25 *like*)/CD4 in healthy control (HC) and different disease stages of melanoma patients (I-II, III, or IV).
26 A Kruskal-Wallis test showed that the percentages were significantly different across different
27 statuses (adjusted *p* = 0.0014). Pairwise comparisons were done by a Mann-Whitney-Wilcoxon test,
28 showing significant differences (adjusted *p* < 0.05) as indicated by (*).

29

30

31

Table I. Patient characteristics in the second dataset

| Patient | Age(years)/sex | Type* | Stage | TNM classification | Previous treatment** |
|---------|----------------|-------|-------|--------------------|----------------------|
| 1 | 82/M | SSM | IA | pT1aN0M0 | - |
| 2 | 62/F | SSM | IB | T1bN0M0 | - |
| 3 | 52/M | SSM | IB | T2aN0M0 | - |
| 4 | 59/F | SSM | IB | pT2aN0M0 | - |
| 5 | 63/F | ALM | IIA | pT2bN0M0 | - |
| 6 | 60/M | ALM | IIC | pT4bN0M0 | OP, Rec |
| 7 | 78/F | SSM | IIC | T4bN0M0 | - |
| 8 | 64/M | SSM | IIIA | pT4N2aM0 | - |
| 9 | 53/F | SSM | IIIA | pT2aN1aM0 | - |
| 10 | 54/F | SSM | IIIB | pT1bN1aM0 | OP, Rec |
| 11 | 63/M | NM | IIIB | pT4bN1aM0 | - |
| 12 | 71/F | SSM | IIIB | T1aN1bM0 | - |
| 13 | 33/F | ALM | IIIB | pT3bN2aM0 | - |
| 14 | 78/M | ALM | IIIC | pT4bN3M0 | - |
| 15 | 71/M | ALM | IV | T4bN3M1c | OP, CT |
| 16 | 62/M | MU | IV | pTxN0M1c | OP, CT |
| 17 | 56/F | MU | IV | pTXN0M1c | OP, CT |
| 18 | 39/F | SSM | IV | pTxNxM1c | OP, CT, RT |
| 19 | 59/F | ALM | IV | TxN3M1c | OP |

* Type: ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; MU, mucosal melanoma; SSM, superficial spreading melanoma

** OP: operation; CT: chemotherapy; RT: radiotherapy; Rec: recurrence.

FIGURE 1




Figure 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

